- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13:54 | Novo Nordisk gains rights to United Laboratories' triple receptor agonist in deal worth $2bn | ||
| 13:54 | Novartis' Fabhalta granted FDA approval to treat ultra-rare kidney disease C3G | ||
| 13:54 | GSK to explore link between Shingrix and dementia risk in new UK research collaboration | ||
| 13:54 | Breaking boundaries in medical affairs: how measurable outcomes redefine success | ||
| Mo | Johnson & Johnson to invest more than $55bn in US over next four years | ||
| Mo | AstraZeneca announces $2.5bn investment in China to boost R&D capabilities | ||
| Mo | Alnylam's Amvuttra granted FDA approval for rare heart disease ATTR-CM | ||
| Mo | From zero to hero: is zero-party data your new best friend for omnichannel HCP engagement? | ||
| Fr | Roche and Oxford BioTherapeutics enter oncology partnership worth over $1bn | ||
| Fr | Johnson & Johnson's Tremfya granted FDA approval to treat Crohn's disease | ||
| Fr | Almirall hosts Skin Academy to advance skin science and dermatology treatments | ||
| Fr | Omnichannel: from theory to successful implementation | ||
| Do | Sanofi expands immunology pipeline by acquiring Dren's bispecific for $600m upfront | ||
| Do | AstraZeneca's Imfinzi granted EC approval for limited-stage small cell lung cancer | ||
| Do | Novartis shares positive phase 3 results for spinal muscular atrophy gene therapy | ||
| Do | Harnessing AI and big data in clinical research | ||
| Mi | Pfizer/Arvinas' vepdegestrant shows promise in phase 3 breast cancer study | ||
| Mi | AbbVie's Elahere shows consistent survival benefits in late-stage ovarian cancer trial | ||
| Mi | Novo shares phase 3 results for obesity candidate CagriSema in diabetes patients | ||
| Mi | Breaking down the barriers | ||
| 18.03. | Boehringer Ingelheim and Salipro Biotech enter drug development partnership | ||
| 18.03. | AstraZeneca to expand cell therapy capabilities with $1bn EsoBiotec acquisition | ||
| 18.03. | NICE recommends Pharming's Joenja as first treatment for ultra-rare immune disease APDS | ||
| 17.03. | Bristol Myers Squibb granted EC approval for Breyanzi in follicular lymphoma | ||
| 17.03. | Roche to launch new innovation centre at Harvard's Enterprise Research Campus |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
